NCT00718354.

Study name	Randomized, phase III‐b, multi‐centre, open‐label, parallel study of enoxaparin (low molecular weight heparin) given concomitantly with chemotherapy vs chemotherapy alone in patients with inoperable gastric and gastro‐oesophageal cancer
Methods	Randomised, open‐label, multicentre study. Methods of randomisation and allocation concealment unclear
Participants	Patients with inoperable (locally advanced) or metastatic newly diagnosed gastric or gastro‐oesophageal cancer
Interventions	Intervention: LMWH, enoxaparin (1 mg/kg SC once daily) in addition to standard chemotherapy up to 6 months Control: standard chemotherapy (up to 6 cycles)
Outcomes	Primary outcome: event‐free survival (composite endpoint of overall survival plus free of symptomatic VTE) Secondary outcomes: incidence of symptomatic VTE, overall survival, major and minor bleeding during chemotherapy or up to 30 days after last dose is provided, serious adverse events, all reported adverse events, HIT
Starting date	July 2008
Contact information	Maganji JM, mmaganji@tri‐london.ac.uk
Notes	NCT00718354 Study status in ClinicalTrials.gov is "complete."